A detailed history of Vanguard Group Inc transactions in Immunovant, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 6,509,753 shares of IMVT stock, worth $179 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,509,753
Previous 6,478,304 0.49%
Holding current value
$179 Million
Previous $209 Million 17.9%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$25.1 - $31.61 $789,369 - $994,102
31,449 Added 0.49%
6,509,753 $172 Million
Q1 2024

May 10, 2024

BUY
$30.27 - $43.79 $19.7 Million - $28.5 Million
650,506 Added 11.16%
6,478,304 $209 Million
Q4 2023

Feb 14, 2024

SELL
$31.31 - $44.19 $12.7 Million - $17.9 Million
-405,348 Reduced 6.5%
5,827,798 $246 Million
Q3 2023

Nov 14, 2023

BUY
$18.55 - $39.96 $14.2 Million - $30.6 Million
764,530 Added 13.98%
6,233,146 $239 Million
Q2 2023

Aug 14, 2023

BUY
$14.2 - $23.75 $4.61 Million - $7.72 Million
324,907 Added 6.32%
5,468,616 $104 Million
Q1 2023

May 15, 2023

BUY
$15.27 - $19.72 $1.14 Million - $1.47 Million
74,590 Added 1.47%
5,143,709 $79.8 Million
Q4 2022

Feb 10, 2023

BUY
$6.59 - $17.75 $7.04 Million - $19 Million
1,068,669 Added 26.71%
5,069,119 $90 Million
Q3 2022

Nov 14, 2022

BUY
$3.93 - $6.37 $3,761 - $6,096
957 Added 0.02%
4,000,450 $22.3 Million
Q2 2022

Aug 12, 2022

BUY
$3.38 - $5.65 $790,176 - $1.32 Million
233,780 Added 6.21%
3,999,493 $15.6 Million
Q1 2022

May 13, 2022

SELL
$5.06 - $8.77 $346,134 - $599,920
-68,406 Reduced 1.78%
3,765,713 $20.8 Million
Q4 2021

Feb 14, 2022

BUY
$7.33 - $9.32 $621,825 - $790,643
84,833 Added 2.26%
3,834,119 $32.7 Million
Q3 2021

Nov 12, 2021

SELL
$7.01 - $11.37 $1.76 Million - $2.86 Million
-251,411 Reduced 6.28%
3,749,286 $32.6 Million
Q2 2021

Aug 13, 2021

BUY
$9.4 - $16.85 $37.6 Million - $67.4 Million
4,000,697 New
4,000,697 $42.3 Million

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.